HC Wainwright Issues Pessimistic Forecast for STOK Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at HC Wainwright lowered their FY2029 earnings per share (EPS) estimates for Stoke Therapeutics in a research report issued on Friday, May 8th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings per share of $1.63 for the year, down from their prior forecast of $1.79. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($3.41) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ FY2030 earnings at $3.74 EPS.

Several other research analysts also recently issued reports on the company. Canaccord Genuity Group lifted their price objective on Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. Chardan Capital reiterated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 18th. Weiss Ratings reissued a “hold (c)” rating on shares of Stoke Therapeutics in a research report on Friday, April 10th. Wedbush boosted their price target on Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Finally, BTIG Research restated a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $41.83.

Stoke Therapeutics Price Performance

STOK stock opened at $32.64 on Tuesday. The company’s 50 day simple moving average is $34.23 and its 200-day simple moving average is $32.00. The firm has a market capitalization of $2.03 billion, a PE ratio of -11.62 and a beta of 1.20. Stoke Therapeutics has a 12 month low of $8.70 and a 12 month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. The firm had revenue of $6.23 million for the quarter, compared to analysts’ expectations of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 51.16%.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently bought and sold shares of STOK. Kestra Advisory Services LLC acquired a new position in Stoke Therapeutics during the fourth quarter worth approximately $26,000. KBC Group NV purchased a new position in Stoke Therapeutics during the first quarter worth approximately $36,000. Harbour Investments Inc. boosted its holdings in shares of Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after purchasing an additional 898 shares during the last quarter. Generali Investments Management Co LLC purchased a new stake in shares of Stoke Therapeutics during the 3rd quarter valued at $41,000. Finally, BNP Paribas Financial Markets grew its stake in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares during the period.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 4,628 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $145,041.52. Following the sale, the general counsel directly owned 28,836 shares of the company’s stock, valued at approximately $903,720.24. This trade represents a 13.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Adrian R. Krainer sold 33,243 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total value of $1,321,076.82. Following the completion of the sale, the director owned 283,302 shares of the company’s stock, valued at $11,258,421.48. This trade represents a 10.50% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 69,699 shares of company stock worth $2,526,714. Company insiders own 9.50% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.